Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Absci Corp (ABSI)

Absci Corp (ABSI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible BayStreet.ca - Thu Dec 18, 8:54AM CST

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – The healthcare AI market reached $21.66 billion in 2025 and analysts now project growth to $110.61...

CBLL : 21.42 (+0.61%)
ONMD : 1.3300 (+3.10%)
VPT.VN : 0.120 (-4.00%)
LNAI : 0.9860 (-0.62%)
ABSI : 3.56 (+1.14%)
VPTDF : 0.0918 (+1.21%)
Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire - Tue Dec 16, 7:00AM CST

VANCOUVER, Wash. and NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today...

ABSI : 3.56 (+1.14%)
Financial Pressure Turns Healthcare AI From Pilots Into Profits BayStreet.ca - Fri Dec 12, 8:37AM CST

Issued on behalf of VentriPoint Diagnostics Ltd. VANCOUVER – Baystreet.ca News Commentary – Healthcare providers shortened buying cycles from eight months to under seven as financial pressures...

VPT.VN : 0.120 (-4.00%)
CCLD : 3.09 (-1.28%)
ABSI : 3.56 (+1.14%)
LNAI : 0.9860 (-0.62%)
CAI : 28.24 (+0.86%)
VPTDF : 0.0918 (+1.21%)
Platform Oncology Technologies Drive Multi-Indication Treatment Expansion BayStreet.ca - Fri Dec 12, 8:35AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Artificial intelligence and platform-based approaches reshaped cancer treatment development in November...

ONCY : 0.9700 (+1.68%)
SANA : 4.53 (unch)
ABSI : 3.56 (+1.14%)
RXRX : 4.40 (+0.92%)
TEM : 64.26 (-0.71%)
Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization GlobeNewswire - Thu Dec 11, 7:00AM CST

Inhibiting prolactin receptor (PRLR) signaling with the ABS-201 anti-PRLR antibody promotes human hair follicle growth  ex vivo Human ex vivo data validate ABS-201’s potential to reverse follicular...

ABSI : 3.56 (+1.14%)
Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research GlobeNewswire - Wed Dec 10, 7:00AM CST

Partnership aims to destigmatize androgenetic alopecia and highlight the need for new therapeutic options that address the root cause of disease Donovan to share his personal journey at Absci’s...

ABSI : 3.56 (+1.14%)
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia GlobeNewswire - Thu Dec 4, 7:00AM CST

Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational...

ABSI : 3.56 (+1.14%)
Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results GlobeNewswire - Wed Nov 12, 3:05PM CST

Reported interim results for Phase 1 trial for ABS-101 (anti-TL1A) On track to initiate Ph1/2a trial for ABS-201 (anti-PRLR for androgenetic alopecia) in December; hosting KOL seminar on December...

ABSI : 3.56 (+1.14%)
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 GlobeNewswire - Wed Oct 29, 3:05PM CDT

VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the...

ABSI : 3.56 (+1.14%)
Absci to Participate in Upcoming Investor Conferences GlobeNewswire - Mon Oct 27, 7:00AM CDT

VANCOUVER, Wash. and NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced...

ABSI : 3.56 (+1.14%)

Barchart Exclusives

This Dividend Giant Yielding 4.5% Is Wall Street’s Top Telecom Pick for 2026 Barchart - Thu Dec 25, 6:30PM CST
JPMorgan just released a list of its 47 top stock picks for 2026, but only one comes from the telecom industry, a stock that features an attractive yield and improving cash flow outlook. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot